The canonical Wnt/β-Catenin pathway is implicated in the pathogenesis of MM, while miR-30-5p functions as a MM suppressor via targeting the oncogenic Wnt/β-Catenin/BCL9 pathway 73. Here, BCL9 is linked to Miyoshi myopathy.